The data shown in this report seems support that direct application of dobesilate (a drug with a long history of clinical safety that was recently re-discovered as an FGF inhibitor) could serve as a promising new clinical application to temper the most important pathological effects of vitreous hemorrhages in proliferative diabetic retinopathy.

That is a grip of cheese.

“Always look after that girl, doc. She's a queen!”

Puh-lease! I went to a bar mitzvah once. That doesn't make me Jewish.